We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.18%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$496M
AUM Growth
+$22M
(+4.6%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
6.96%
Top 10 Holdings %
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$3.17M |
| 2 |
MPLX
MPLX
|
+$3.04M |
| 3 |
BlackRock Limited Duration Income Trust
BLW
|
+$2.79M |
| 4 |
ABDC
Alcentra Capital Corp
ABDC
|
+$1.98M |
| 5 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$1.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.67M |
| 2 |
ECC
Eagle Point Credit Company
ECC
|
+$5.43M |
| 3 |
ANDX
Andeavor Logistics LP
ANDX
|
+$2.66M |
| 4 |
BlackRock Floating Rate Income Strategies Fund
FRA
|
+$2.25M |
| 5 |
MVC
MVC Capital, Inc.
MVC
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.1% |
| 2 | Real Estate | 16.28% |
| 3 | Energy | 14.42% |
| 4 | Healthcare | 8.59% |
| 5 | Materials | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Bain Capital Specialty
BCSF
$802M
| $956K | 0.19% |
+51,335
| New | +$925K |
|
|
SGEN
152
DELISTED
Seagen Inc. Common Stock
SGEN
| $864K | 0.17% |
10,120
-1,697
| -14% | -$124K |
|
153
Theravance Biopharma
TBPH
$874M
| $846K | 0.17% |
43,442
-7,309
| -14% | -$148K |
|
|
RDUS
154
DELISTED
Radius Health, Inc.
RDUS
| $811K | 0.16% |
31,498
-5,297
| -14% | -$130K |
|
155
Alnylam Pharmaceuticals
ALNY
$36.3B
| $795K | 0.16% |
9,888
-1,671
| -14% | -$132K |
|
156
Amgen
AMGN
$203B
| $762K | 0.15% |
3,939
-658
| -14% | -$126K |
|
|
MNTA
157
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $750K | 0.15% |
57,849
-9,721
| -14% | -$117K |
|
158
Neurocrine Biosciences
NBIX
$17.7B
| $743K | 0.15% |
8,250
-1,396
| -14% | -$130K |
|
159
Biogen
BIIB
$29.9B
| $738K | 0.15% |
3,170
-386
| -11% | -$89.9K |
|
|
PTLA
160
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $722K | 0.15% |
26,910
-4,526
| -14% | -$127K |
|
|
CELG
161
DELISTED
Celgene Corp
CELG
| $712K | 0.14% |
7,171
-1,217
| -15% | -$116K |
|
162
United Therapeutics
UTHR
$26.3B
| $706K | 0.14% |
8,856
-1,492
| -14% | -$120K |
|
163
Gilead Sciences
GILD
$161B
| $699K | 0.14% |
11,032
-1,762
| -14% | -$115K |
|
164
Omeros
OMER
$709M
| $699K | 0.14% |
42,784
-7,184
| -14% | -$123K |
|
165
Vertex Pharmaceuticals
VRTX
$121B
| $689K | 0.14% |
4,068
-688
| -14% | -$122K |
|
166
Halozyme
HALO
$9.72B
| $683K | 0.14% |
44,046
-7,415
| -14% | -$122K |
|
167
Ionis Pharmaceuticals
IONS
$9.35B
| $668K | 0.13% |
11,156
-1,881
| -14% | -$123K |
|
168
Incyte
INCY
$23.5B
| $661K | 0.13% |
8,911
-1,506
| -14% | -$122K |
|
169
Ligand Pharmaceuticals
LGND
$6.02B
| $643K | 0.13% |
10,347
-1,733
| -14% | -$109K |
|
170
Regeneron Pharmaceuticals
REGN
$68.8B
| $630K | 0.13% |
2,271
-381
| -14% | -$113K |
|
171
Vanda Pharmaceuticals
VNDA
$312M
| $630K | 0.13% |
47,470
-7,974
| -14% | -$111K |
|
172
Exelixis
EXEL
$13.9B
| $622K | 0.13% |
35,178
-5,913
| -14% | -$120K |
|
|
ALXN
173
DELISTED
Alexion Pharmaceuticals
ALXN
| $594K | 0.12% |
6,063
-801
| -12% | -$90.3K |
|
174
Puma Biotechnology
PBYI
$406M
| $582K | 0.12% |
54,053
-9,089
| -14% | -$98.1K |
|
|
ICPT
175
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $578K | 0.12% |
8,711
-1,469
| -14% | -$98.6K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, Virtus ETF Advisers held 461 positions worth $496M, up 4.6% from $474M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Virtus ETF Advisers deployed $34.5M of net new capital in Q3 2019, opening 27 new positions and adding to 142 existing holdings. Its largest new stake was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was TriplePoint Venture Growth BDC, an estimated $813K trimmed.
- Virtus ETF Advisers's largest Q3 2019 buy was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
- Virtus ETF Advisers added most to MPLX in Q3 2019, an estimated $3.04M increase.
- Virtus ETF Advisers's biggest Q3 2019 reduction was TriplePoint Venture Growth BDC, cutting an estimated $813K.
- Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2019, selling an estimated $6.67M.
- Virtus ETF Advisers's ten largest holdings make up 10% of its $496M portfolio in Q3 2019.
- Virtus ETF Advisers opened 27 new positions and closed 26 in Q3 2019.
- Virtus ETF Advisers's portfolio value rose 4.6% quarter-over-quarter to $496M.
Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.